FDA+ roundup: Agency re­opens AI dis­cus­sion pa­per for com­ments amid two-day work­shop

The FDA is re­open­ing the com­ment pe­ri­od on its dis­cus­sion pa­per on us­ing ar­ti­fi­cial in­tel­li­gence in drug de­vel­op­ment, co­in­cid­ing with a two-day work­shop on the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER